Biocon Biologics has received approval from the US Food and Drug Administration for the intravenous use of Jobevne ...

The FDA has approved bevacizumab-nwgd, a biosimilar to bevacizumab, for intravenous use across multiple cancer types.

In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

The FDA has set a goal date of Aug. 27, 2025. If approved, the therapy would be branded as Lytenava and be the first ...

The Food and Drug Administration (FDA) has accepted for review a resubmission of the Biologics License Application (BLA) for bevacizumab-vikg (ONS-5010) for the treatment of wet age-related macular ...

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevne™ (bevacizumab-nwgd), ...

Biocon Biologics receives USFDA approval for Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for treating various ...

FDA approves Biocon Biologics' Jobevne, a biosimilar Bevacizumab for cancer treatment, expanding access to affordable ...

Biocon Biologics Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved JOBEVNE™ (bevacizumab-nwgd), a ...

Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.